Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue vs Hydroxocobalamin for Vasoplegia Risk in Cardiac Surgery
NCT03446599Phase 2Withdrawn
- Sponsor
- Dartmouth Health
- Start
- Nov 2019
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxocobalamin, methylene blue in Vasoplegia, sponsored by Dartmouth Health. Planned start Nov 2019; status: withdrawn.
02
Drugs
hydroxocobalaminmethylene blue
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on NCT03446599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446599.